Table 9.
Adverse events in each group while on ATT
| HIV + (n = 150) | HIV- (n = 155) | Overall (n = 305) | |
|---|---|---|---|
| Total patients experiencing adverse event(s) |
69 (46.0%) |
74 (47.7%) |
143 (46.9%) |
| Total patients experiencing serious adverse event(s) |
44 (29.3%) |
3 (1.9%) |
47 (15.4%) |
| IRIS* |
14 (9.3%) |
0 |
14 (4.6%) |
| Anaemia (new on treatment)* |
9 (6.0%) |
0 |
9 (3.0%) |
| Drug-induced hepatotoxicity* |
5 (3.3%) |
0 |
5 (1.6%) |
| Isoniazid-induced psychosis* |
1 (0.7%) |
0 |
1 (0.3%) |
| Stevens-Johnson syndrome* |
1 (0.7%) |
0 |
1 (0.3%) |
| Peripheral neuropathy* |
2 (1.3%) |
0 |
2 (0.7%) |
| Haemoptysis* |
0 |
6 (3.9%) |
0 |
| Itch |
9 (6.0%) |
2 (1.3%) |
11 (3.6%) |
| Rash |
11 (7.3%) |
2 (1.3%) |
13 (4.3%) |
| Nausea/vomiting |
47 (31.3%) |
71 (45.8%) |
118 (38.7%) |
| Diarrhoea |
17 (11.3%) |
24 (15.5%) |
41 (13.4%) |
| Abdominal pain | 17 (11.3%) | 26 (16.8%) | 43 (14.1%) |
* Classified as serious adverse events.